Jan 05,2022

In Vitro Evaluation of Miniaturized Amperometric Enzyme Sensor Based on the Direct Electron Transfer Principle for Continuous Glucose Monitoring

The bacterial derived flavin adenine dinucleotide (FAD)-dependent glucose dehydrogenase (FADGDH) is the most promising enzyme for the third-generation principle-based enzyme sensor for continuous glucose monitoring (CGM).

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 19,2022

Use of Retrospective Continuous Glucose Monitoring Data Is Underrated and Underused

This article presents a series of patient case examples that illustrate how the use of retrospective data enables to identify and effectively address patterns of problematic glycemia.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 19,2022

Development of a Novel Insulin Sensor for Clinical Decision-Making

Researchers carried out the development and optimization of a novel decentralized disposable insulin electrochemical sensor focusing on obtaining high analytical and operational performance toward achieving a true point-of-care insulin testing device for clinical on-site application.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 20,2022

Health2Sync Expands Product Offering In Chronic Disease Management With Real Word Data Integration And Analytics

Taiwan-based digital health startup Health2Sync makes further inroads in personalized chronic disease management with an expanded coverage of the patient journey with the latest version of its mobile application capturing continuous glucose monitoring (CGM) data to improve overall lifestyles.

PRODUCT

#dtx

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 01,2022

Rimidi Achieves 72% Revenue Growth, Grows Client Base by 141% in 2021

Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives, today announced that the company increased its revenue by 72% and grew its client base by triple digits in 2021.

PRODUCT

#cgm

#bgm

View Analyst & Ambassador Comments
Go to original news
Feb 01,2022

The Benefits of Utilizing Continuous Glucose Monitoring of Diabetes Mellitus in Primary Care: A Systematic Review

The study aims to show if CGM/is-CGM improves glycemic control, decreases rates of hypoglycemia, and improves staff/physician satisfaction in primary care. If so, what subgroups of patients with diabetes are most likely to benefit?

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 07,2022

Accuracy of Continuous Glucose Monitors for Inpatient Diabetes Management

In hospitalized patients, continuous glucose monitoring (CGM) may improve glycemic control, prevent hypoglycemic events, and reduce staff workload compared with point-of-care (POC) capillary glucose monitoring. This study is to evaluate CGM accuracy and safety of use in the inpatient setting, two versions of CGM sensors were placed on 43 and 34 adult patients with diabetes admitted to non-intensive care unit (ICU) medical wards, respectively.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 14,2022

ASCENSIA DIABETES CARE ANNOUNCES FDA APPROVAL OF THE EVERSENSE E3 CONTINUOUS GLUCOSE MONITORING SYSTEM FOR USE FOR UP TO 6 MONTHS

Ascensia Diabetes Care, a global diabetes care company, announces that its partner Senseonics Holdings, Inc. (NYSE American: SENS) has received approval from the U.S. Food and Drug Administration (FDA) for the next-generation Eversense ® E3 Continuous Glucose Monitoring (CGM) System. Ascensia plans to make the Eversense E3 sensor, which can be used for up to 6 months, available to patients in the U.S. during the second quarter of 2022.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 16,2022

Signos Launches a First-of-its-Kind 20,000 Person Study on CGM Use Paired With an AI-Powered Health App to Unlock the Role of Glucose Responses in Health Outcomes for All

Today, Signos announced a first-of-its-kind 20,000 person study on the effects of combining real-time continuous glucose monitor (CGM) use and a mobile health app to improve health outcomes and weight management.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 01,2022

Military Members, Families and Retirees Get Simplified Access to Abbott’s FreeStyle® Libre 2 system Through TRICARE®

Abbott announced today that its FreeStyle® Libre 2 flash glucose monitoring system (CGM) is now available as a brand-name formulary pharmacy benefit to military members, their families and retirees with TRICARE® health coverage. This will make it easier for TRICARE members to access industry-leading monitoring technology1 to manage their diabetes.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM